Novartis Ag

Novartis Pharma Gmbh

Kaspar Zimmermann

Mahavir Prashad

Yves Auberson

Andrew James Culshaw

Yugang Liu

Robert Portmann

Samuel Hintermann

Peter Gull

Max Peter Seiler

Dean Franklin Rigel

Kai Lin

Hong-Yong Kim

Allan Hallett

Beat Weidmann

The invention provides compounds of formula (I) wherein R, R, R, R, and Rare as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals. 

Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain

The present invention relates to novel benzo[1,2,5]oxadiazoles and benzo[1,2,5]thiadiazoles of formula (I) wherein X is O or S, Ris 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-F-ethylamino)-thiazol-2-yl or a group of formula (a) wherein Y is CH or N, Ris NHCH, NHCH, N(CH)CH, N(CH), N(CH), NH(CH)F, NH(CH)F, N(CH)(CH)F, N(CH)&#x2014;(CH)F, O&#x2014;(CH)F, O&#x2014;(CH)F, CONH(CH)nF or CONH(CH)F (n being in each case 2 to 4) and Ris hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form; their preparation, their use as markers in diagnosis and compositions containing them.

Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers

The invention provides compounds of formula (I) wherein R is as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals, for use in the treatment of any state associated with high levels of activeted PARP.

Indoloquinazolinones

Growing community of inventors

Oberwil, Switzerland

Kaspar Zimmermann